Complement System

THE COMPLEMENT SYSTEM 

The complement system helps or “complements” the ability of antibodies ant ibodies and phagocytic cells to clear pathogens from an organism. It is part of the immune system called the innate immune system that is not adaptable and does not change over the course of an individual's lifetime. However, it can be recruited recru ited and brought into action by the adapt ive immune system. The complement system consists of a number of small proteins found in the blood, generally synthesized by the liver, and normally circulating as inactive precursors (pro-proteins). When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an a mplifying mplifying cascade o f further cleavages. The end-result o f this activation cascade is massive amplification of the response and act ivation of the cell-killing membrane attack complex. Over 25 proteins and protein fragments make up the complement system, including serum proteins, serosal proteins, and cell membrane receptors. They account for about 5% of the globulin g lobulin fraction of blood serum. Three biochemical pathways activate the complement system: the classical complement [1]  pathway, the alternative complement pathway, and the mannose-binding lectin pathway.

History In the late 19th century, Hans Ernst August Buchner found that blood serum contained a "factor" or "principle" capable of killing bacteria. In 1896, Jules Bordet, a young Belgian scientist in Paris at the Pasteur Institute, demonstrated that this principle had two components: o ne that maintained this effect after being heated, and one that lost this effect after being heated. The heat-stable component was responsible respo nsible for the immunity against specific spec ific microorganisms, whereas the heat-sensitive (heat-labile) (heat- labile) component was responsible for the non-specific antimicrobial activity conferred by all normal serum. This heat -labile component is what we now call "complement." The term "complement" was introduced by Paul Ehrlich in the late 1890s, as part of his larger  theory of the immune system. According Acco rding to this theory, the immune system syste m consists of cells that have specific receptors on their surface to recognize antigens. Upon immunization with an antigen, more of these receptors are formed, and they are then t hen shed from the cells to circulate in the blood. These receptors, which we now call "antibodies," were called by Ehrlich "amboceptors" to emphasize their bifunctional binding capacity: They recognize and bind to a specific antigen, but they also recognize and bind to the heat-labile antimicrobial component of  fresh serum. Ehrlich, therefore, named this heat-labile component "complement," because it is something in the blood that "complements" the cells of the immune system. In the early half of 

the 1930s, a team led by the renowned Irish researcher, Jackie Stanley, stumbled upon the allimportant opsonization-mediated effect of C3b. Building o ff Ehrlich's work, Stanley's team  proved the role of complement in both the innate as well as the cell-mediated immune response. Ehrlich believed that each antigen-specific amboceptor has its own specific complement, whereas Bordet believed that there is only one type of complement. In the early 20th century, this controversy was resolved when it became understood that complement can act in combination with specific antibodies, or on its own in a non-specific way.

Functions of the Complement

Membrane attack complex causing cell lysis. This article is about an aspect of the immune system. For other uses, see complement (disambiguation). The following are the basic functions of the complement 1. 2. 3. 4. 5.

Opsonization - enhancing phagocytosis of antigens Chemotaxis - attracting macrophages and neutrophils Lysis - rupturing membranes of foreign cells Clumping of antigen-bearing agents Altering the molecular structure of viruses

Overview The proteins and glycoproteins that constitute the complement system are synthesized by the liver hepatocytes. But significant amounts are also produced by tissue macrophages, blood  monocytes, and epithelial cells o f the genitourinal tract and gastrointestinal tract. The three  pathways of activation all generate homologous variants of the protease C3-convertase. The classical complement pathway typically requires ant igen:antibody complexes for activation (specific immune response), whereas the alternative and mannose-binding lectin pathways can be activated by C3 hydrolysis or antigens without the presence of antibodies (non-specific immune response). In all three pathways, a C3-convertase cleaves and activates component C3, creating C3a and C3b, and causing a cascade of further cleavage and activation events. C3b binds to the surface of pathogens, leading to greater internalization by phagocytic cells by opsonization. C5a is an important chemotactic protein, helping recru it inflammatory cells. Both C3a and C5a have

anaphylatoxin activity, directly triggering degranulation of mast cells as well as increasing vascular permeability and smooth muscle contraction. C5b initiates the membrane attack   pathway, which results in the membrane attack complex (MAC), consisting of C5b, C6, C7, C8, [2] and polymeric C9. MAC is the cytolytic endproduct of the complement cascade; it forms a transmembrane channel, which causes osmotic lysis of the target cell. Kupffer cells and other  macrophage cell types help clear complement-coated pathogens. As part of the innate immune system, elements of the complement cascade can be found in species earlier than vertebrates; most recently in the protostome horseshoe crab species, putting the origins of the s ystem back  further than was previously thought.

Classical pathway Main article: Classical complement pathway

Figure 2. The classical and a lternative complement pathways. The classical pathway is triggered by activation of the C1-complex (composed of 1 molecule of  C1q, 2 molecules of C1r and 2 molecules of C1s, thus forming C1qr 2s2), which occurs when C1q   binds to IgM or IgG complexed with antigens (a single IgM can initiate the pathway, while multiple IgGs are needed), or when C1q binds directly to the surface of the pathogen. Such  binding leads to conformational changes in the C1q molecule, which leads to the activation of  two C1r (a serine protease) molecules. They then cleave C1s (another serine protease). The 2 2 C1r  s component now splits C4 and then C2, producing C4a,C4b,C2a,and C2b. C4b and C2a  bind to form the classical pathway C3-convertase (C4b2a complex), which promotes cleavage of 

C3 into C3a and C3b; C3b later joins with C4b2a (the C3 convertase) to make C5 convertase (C4b2a3b complex). The inhibition of C1r and C1s is controlled by C1-inhibitor. C3-convertase can be inhibited by Decay accelerating factor (DAF), which is bound to erythrocyte plasma membranes via a GPI anchor. Paroxysmal nocturnal hemoglobinuria is caused by complement breakdown of RBCs due to an inability to make GPI. Thus the RBCs are not protected by GPI anchored proteins such as DAF.

Alternative pathway The alternative pathway is triggered by spontaneous C3 hydrolysis directly due to the breakdown of the thioester bond via condensation reaction (C3 is mildly unstable in aqueous environment) to form C3a and C3b. It does not rely on a pathogen-binding antibodies like the other  [1]  pathways. C3b is then capable of covalently binding to a pathogenic membrane surface if it is near enough. If there is no pathogen in the blood, the C3a and C3b protein fragments will be deactivated by rejoining with each ot her. Upon binding with a cellular membrane C3b is bound   by factor B to form C3bB. This complex in presence of factor D will be cleaved into Ba and Bb. Bb will remain covalently bonded to C3b to form C3bBb, which is the alternative pathway C3convertase. The protein C3 is produced in the liver. The C3bBb complex, which is "hooked" onto the surface of the pathogen, will then act like a "chain saw," catalyzing the hydrolysis of C3 in the blood into C3a and C3b, which positively affects the number of C3bBb hooked onto a pathogen. After hydrolysis of C3, C3b complexes to  become C3bBb3b, which cleaves C5 into C5a and C5b. C5 b with C6, C7, C8, and C9 (C5b6789) complex to form the membrane attack complex, also known as MAC, which is inserted into the cell membrane, "punches a hole," and initiates cells lysis. C5a and C3a are known to trigger mast cell degranulation.

Lectin pathway (MBL - MASP) The lectin pathway is homologous to the classical pathway, but with the opsonin, mannose binding lectin (MBL), and ficolins, instead of C1q. This pathway is activated by binding mannose-binding lectin to mannose residues on the pathogen surface, which activates the MBLassociated serine proteases, MASP-1, and MASP-2 (very similar to C1r and C1s, respectively), which can then split C4 into C4a and C4b and C2 into C2a and C2b. C4b and C2a then bind  together to form the C3-convertase, as in the classical pathway. Ficolins are homologous to MBL and function via MASP in a similar way. In invertebrates without an adaptive immune system, ficolins are expanded and their binding specificities diversified to compensate for the lack of   pathogen-specific recognition molecules.

Activation of complements by antigen-associated antibody In the classical pathway, C1 binds with its C1q subunits to Fc fragments (made of CH2 region) of IgG or IgM, which has formed a complex with antigens. C4b and C3b are also able to bind to [5][10][13] antigen-associated IgG or IgM, to its Fc portion (See Figure 2).

Such immunoglobulin-mediated binding of the complement may be interpreted as that the complement uses the ability of the immunoglobulin to detect and bind to non-self antigens as its guiding stick. The complement itself is able to bind non-self pathog ens after detecting their  [13]  pathogen-associated molecular patterns (PAMPs), however, utilizing specificity of antibody, complements are able to detect non-self enemies much more specifically. There must be mechanisms that complements bind to Ig but would not focus its function to Ig but to the antigen. Figure 2 shows the classical and the alternative pathways with the late steps of complement [5][10][13] activation schematically. Some components have a variety of binding sites. In the classical pathway C4 binds to Ig-associated C1q and C1r 2s2 enzyme cleave C4 to C4b and 4a. C4b binds to C1q, antigen-associated Ig (specifically to its Fc po rtion), and even to the microbe surface. C3b binds to antigen-associated Ig and to the microbe surface. Ability of C3b to bind to antigen-associated Ig would work effectively against antigen-antibody immune complexes to make them soluble. In the figure, C2b refers to the larger of the C2 fragments.

Regulation of the complement system The complement system has the potential to be extremely damaging to host tissues, meaning its activation must be tightly regulated. The complement system is regulated by complement control  proteins, which are present at a higher concentration in the blood plasma than the complement  proteins themselves. Some complement control proteins are present on the membranes of selfcells preventing them from being targeted by complement. One example is CD59, also known as  protectin, which inhibits C9 polymerisation during the formation of the membrane attack  complex. The classical pathway is inhibited by C1-inhibitor, which binds to C1 to prevent its activation.

Role in disease It is thought that the complement system might play a role in many diseases with an immune component, such as Barraquer-Simons Syndrome, asthma, lupus erythematosus, glomerulonephritis, various forms of arthritis, autoimmune heart disease, multiple sclerosis, [17][18] inflammatory bowel disease, and ischemia-reperfusion injuries. and rejection of  [19] transplanted organs. The complement system is also becoming increasingly implicated in diseases of the central nervous system such as Alzheimer's disease and other neurodegenerative conditions such as [20][21][22] spinal cord injuries. Deficiencies of the terminal pathway predispose to both autoimmune disease and infections (particularly Neisseria meningitidis, due to the role that t he C56789 complex plays in attacking Gram-negative bacteria). Mutations in the complement regulators factor H and membrane cofactor protein have been [23][24] associated with atypical haemolytic uraemic syndrome. Moreover, a common single nucleotide polymorphism in factor H (Y402H) has been associated with the common eye disease

[25]

age-related macular degeneration. Polymorphisms of complement component 3, complement factor B, and complement factor I, as well as deletion of co mplement factor H-related 3 and  complement factor H-related 1 also affect a person's risk of developing age-related macular  [26] degeneration. Both of these disorders are currently thought to be due to aberrant complement activation on the surface of host cells. Mutations in the C1 inhibitor gene can cause hereditary angioedema, an autoimmune condition resulting from reduced regulation of the complement pathway. Mutations in the MAC components of complement, especially C8, are o ften implicated in recurrent Neisserial infection.

Modulation by infections Recent research has suggested that the complement system is manipulated during HIV/AIDS to [27] further damage the body.